ArticleEuropean journal of pediatrics2025
Transient pseudohypoaldosteronism type I in infants with urinary tract infections and/or uropathy: insights from a French multicenter cohort.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the first year of life, and especially in the first 6 months, urinary tract infections, congenital anomalies of the kidney and urinary tract (CAKUT)-particularly obstructive types-and the coexistence of both factors may lead to transient resistance to aldosterone. This condition is characterized by fluid and salt loss despite significant activation of the renin-angiotensin-aldosterone system, and by electrolyte disturbance featuring hyponatremia, hyperkalemia, and metabolic acidosis with a normal anion gap. Transient resistance to aldosterone is not widely recognized by clinicians. Our objective was to describe the clinical presentations and management strategies in order to propose a comprehensive diagnostic approach.
methodsWe conducted a 13-year retrospective study involving 35 children from eight centers across France, as well as one child from Switzerland.
resultsMost of the children in our cohort were under 6 months of age (68.6% male). The clinical presentation of pseudohypoaldosteronism was variable and often similar to that of adrenal insufficiency. The pyelonephritis diagnosis was retained in 94.3% of the cases and uropathy was present in 85.7% of the children. Treatment was primarily symptomatic, and included intravenous hydration, salt supplementation, correction of potassium levels, and antibiotic therapy when pyelonephritis was diagnosed.
conclusionTransient type I pseudohypoaldosteronism should be promptly considered in any infant presenting with a deteriorating general condition and fluid and electrolyte imbalances, particularly hyponatremia and hyperkalemia, in the context of acute pyelonephritis and/or uropathy. WHAT IS KNOWN: • Transient type I pseudohypoaldosteronism affects infants under 1 year of age with congenital anomalies of the kidney and urinary tract during acute pyelonephritis. • Treatment mostly consists of antibiotics and parenteral fluids. WHAT IS NEW: • This is the first article to report on 34 cases from a single country. • The importance of renal ultrasound in the context of urinary tract infection with salt wasting symptoms in infants without known congenital anomalies the kidney and urinary tract. • The importance of assessing hydro-electrolytic status in cases of urinary tract infection in infants under 6 months with or without known congenital anomalies of the kidney and urinary tract. • A decision tree for the diagnostic approach of transient type I pseudohypoaldosteronism.
Indexed as
Identifiers
41212330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.